When plasma from patients treated with cetuximab (obtained four hours after infusion) was used to opsonize tumor cell lines, 2.5% plasma was sufficient for maximal saturation of EGFR on different cell lines (Figures 5(a)–5(d)). The gene discussed is EGFR; the disease is neoplasm.